ERBB2 and breast carcinoma: The use of treatments targeting the ER and HER2 in patients with early-stage breast cancer has resulted in noticeable reductions in tumor recurrence and death, but resistance to these treatments often due to the activation of alternative survival pathways can develop and cause disease progression (Dhillon 2013).